Our aim is to transform problems into solutions in the field of lymphoma, in order to associate its diagnosis with a therapeutic approach adapted to the tumour’s biology
B-cell non-Hodgkin lymphomas (B-NHL) are haematological cancers. Their origin lies in a close cooperation between the genetic alterations of the lymphoma and the support of surrounding cells, which is known as the tumour microenvironment.
For a treatment to be effective, it is mandatory to attack the lymphoma cells using targeted therapies, and to dismantle this protective lymphoma-microenvironment network.
The group studies the crosstalk between lymphoma cells and its immune microenvironment. This knowledge may allow establishing the basis to manipulate these interactions and the design of novel, targeted and personalised therapies.
For this purpose, the group has generated next - generation ex vivo 3D cultures composed of cells from patients diagnosed of B-NHL at HCB with associated genetic information, including tumour microenvironment cells. These systems constitute robust lymphoma models to test novel targeted therapies, immunotherapies and combinations.
The group’s objective is unquestionably to conduct basic research in order to improve the treating options for lymphoma patients, characterising their mechanisms of action and resistance.
The group has a privileged organisation working in a multidisciplinary setting, where collaboration among basic researchers, haematologists and pathologists facilitates bench-to bedside translation.